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Contemporary cancer treatment in the developed world has ena-
bled most young cancer patients to survive their disease. With suc-
cessful treatment comes an opportunity-even a mandate-to address
quality-of-life issues, including the future fertility of the survivors.
Practice guidelines from both the American Society of Clinical Oncol-
ogy and the American Society for Reproductive Medicine (ASRM)
emphasize early discussion of fertility preservation options, prompt
referral to an appropriate specialist, and the promotion of research
and clinical trials to improve reproductive preservation.'
This Article will review the medical options available for fertility
preservation, including options for gamete donation, and will touch on
the limits of medical technology to address social and cultural
problems.
The diagnosis of cancer in a young person is a devastating event.
Life itself is at stake. Furthermore, our current-albeit often success-
ful-treatments for cancer, such as extirpative surgery, radiation, and
chemotherapy, are painful, humiliating, and perilous ordeals.2 An op-
portunistic infection may take advantage of the compromised immune
system, or permanent damage may be done to the heart, kidneys,
lungs, or brain-sometimes leading to death and sometimes leaving
the individual alive but disabled. Compared to the possible effects on
vital organs, the effects of surgery, radiation, and chemotherapy on
the reproductive system are of lesser significance. Nonetheless, they
have important psychological and social implications. Fortunately, the
past two decades have seen significant advances in fertility preserva-
tion after cancer treatment.
* Associate Professor of Clinical Reproductive Medicine, Weill Cornell Medical College.
1. Stephanie J. Lee et al., The American Society of Clinical Oncology Recommendations on
Fertility Preservation in Cancer Patients, 24 J. CLINICAL ONCOLOGY 2917, 2927 (2006); Ethics
Comm. of the ASRM, Fertility Preservation and Reproduction in Cancer Patients, 83 FERTILITY
& STERILITY 1622, 1627 (2005).
2. The medical slang for these treatments is "slash, burn, and poison."
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II. OVERVIEW OF FERTILITY PRESERVATION
Fertility preservation is a consideration for some, but not all, people
undergoing cancer treatment. Fertility has been spared in more pa-
tients as treatments for cancer have become not only more successful,
but also less toxic. For example, an invasive, potentially lethal malig-
nant melanoma may be successfully treated by surgery alone (wide
excision and lymph node removal) without impact on future fertility.
Some chemotherapeutic agents are less toxic than others; sometimes
gonads can be shielded from-or even moved out of-the radiation
fields. However, treatment can compromise fertility when, for exam-
ple, it includes surgery to remove reproductive organs, radiation fields
that include the pelvis, or chemotherapy toxic to the gonads. The de-
gree of compromise depends on factors including the age of the per-
son with cancer, the field and dose of radiation, and the toxicity and
dose of chemotherapy. Bone marrow transplants, toxic chemothera-
peutic regimens designed to destroy all rapidly dividing cells (with the
destroyed blood producing cells of the bone marrow restored with
cells from a donor) that is generally reserved for aggressive cancers or
cancer recurrence, invariably lead to infertility.
It is also important to emphasize that not all medically indicated
fertility preservation is for cancer patients. Some people with benign
disease require treatment that may be harmful to future fertility. For
example, extensive benign surgery (for endometriosis or a benign ova-
rian or testicular tumor, for example) may result in infertility.
Gonadotoxic chemotherapy may be indicated for lupus, rheumatoid
arthritis, or ulcerative colitis. Bone marrow transplants may be per-
formed in cases of serious noncancerous diseases such as Beta Thalas-
semia. Some women may have a known genetic predisposition to
premature ovarian failure (such as Fragile X carriers and women with
Turner's Syndrome variants). Additionally, for some women who are
BrCa carriers and who have a high risk of developing ovarian cancer,
surgical removal of the ovaries at a young age may be recommended
for prevention of ovarian cancer.
Finally, in the developed world, where education and career build-
ing take a long time, childbearing may be delayed and infertility may
result. We see the technology developed for medical fertility preser-
vation increasingly used to address these social needs.
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A. Fertility Preservation for Men
Any quick overview of the medical means of fertility preservation
will reveal a gender discrepancy. 3 The technology to freeze (or cry-
opreserve) germ cells is not equal. Sperm are tiny cells. They have
been successfully frozen, thawed, and used to create human
pregnancies since 1953.4 The procedure requires little technology and
is relatively inexpensive, with little or no medical risk and a high rate
of success. Men facing therapy toxic to the testes, if appropriately
counseled and informed, can choose to quickly freeze and "bank"
sperm-usually millions of sperm-with low risk, relatively low cost,
and without causing a delay in the initiation of cancer therapy. While
there may not yet be universal access to sperm cryopreservation, it is
within reach.
B. Fertility Preservation for Women
For women, the issues are different. The mature egg is a large cell
that freezes only with difficulty. Generally, only one egg is formed
each month, and it is formed only at a certain time. In order to pro-
duce more than a single egg, a woman must take strong injectable
fertility drugs. Her eggs must be retrieved under anesthesia by a nee-
dle puncture of the ovary during in vitro fertilization (IVF). At each
stage of the procedure, she encounters risks-from the hormones,
from the impact on the ovaries caused by the production of multiple
eggs, and from the puncture. IVF is stressful, emotionally taxing, and
expensive. Finally, IVF takes time. The planned cancer treatment
will be delayed between two to five weeks.
Even then, successful freezing of eggs is not a proven therapy. The
mature egg is a large cell containing much water. If it is frozen in the
same way that sperm are frozen, large ice crystals will form inside the
egg. These ice crystals can damage delicate structures within the cell.
Because water expands when it freezes (think of a can of soda in the
freezer) the cell membrane of the egg can rupture. Thus, egg freezing
is a delicate process. The water must be slowly removed from the egg,
dehydrating it without damaging it. Antifreeze-like chemicals
(cryoprotectants) help the dehydration process and also replace some
of the water in the egg with substances that do not expand when fro-
zen. Finally, methods have been developed to freeze the egg so
3. Tobias S. Kohler et al., Results from the Survey for Preservation of Adolescent Reproduction
(SPARE) Study: Gender Disparity in Delivery of Fertility Preservation Message to Adolescents
with Cancer, 28 J. ASSISTED REPROD. GENETICs 269 (2011).
4. Yoel Shufaro & Joseph G. Schenker, Cryopreservation of Human Genetic Material, AN-
NALs N.Y. ACAD. Sci., Sept. 2010, at 220, 220.
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quickly that small amounts of water still present in the egg can be-
come solid without forming ice crystals (vitrification). A method for
successfully freezing eggs has taken a long time to develop, is difficult
to do, is dependent on the skill and experience of the operator, and
should still be considered experimental.5 Only in the last few years
have medical practitioners achieved reasonable success rates.6
An alternative to egg freezing is the freezing of embryos (eggs that
have previously been fertilized by sperm and have become embryos).
Embryo freezing is not as difficult as egg freezing, it has a proven
track record, and it is not considered experimental. However, embryo
freezing requires that the young woman have a committed partner or
use donor sperm. The procedure still involves fertility drugs and the
retrieval of eggs and thus involves medical risk, treatment delays, and
considerable expense. In addition, we add ethical, emotional, and le-
gal problems when we move from the freezing of gametes to the crea-
tion (and potential disposition) of human embryos.
C. Fertility Preservation for Children
Unfortunately, none of the above techniques are applicable to pre-
adolescent children. The current recourse for children is to surgically
remove and freeze sections of the ovary or testes. This technology is
the most experimental of all, and it raises serious concerns about pa-
rental rights, informed consent, and the emotional and social implica-
tions of the frozen tissue once it exists.
D. Refusing Fertility Preservation
The medical, legal, and psychological complexity of all these meth-
ods means that cancer patients may choose to demur, even when these
methods have a reasonable statistical chance of success. The young
cancer patient faces physical and emotional ordeals, as well as a
daunting array of difficult choices to make in a short period. Some-
times one less procedure is a good choice. The importance of being a
parent varies for individuals, and the importance of being a genetic
parent varies as well. Hopefully the advisors-oncologists, reproduc-
tive endocrinologists, psychologists, lawyers, and others-can support
not only patients who choose to pursue fertility preservation, but also
those who choose to decline it.
5. See Practice Comm. of the ASRM & Practice Comm. of the Soc'y for Assisted Reprod.
Tech., Ovarian Tissue and Oocyte Cyropreservation, 90 FERTILITY & STERILITY S241 (Supp. III
2008).
6. See Nicole Noyes et al., Oocyte Cryopreservation as a Fertility Preservation Measure for
Cancer Patients, 23 REPROD. BIOMEDICINE ONLINE 323 (2011).
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III. DONOR EGG OR SPERM AS AN OPTION
For some people who wish to be parents, genetic connection to their
children is not a major concern. In some circumstances, people would
prefer to have nongenetically related children; for example, people
who carry a deleterious gene that they prefer not to transmit. Thus,
medical practitioners should be careful to include discussions, some-
times even detailed ones, of parenting alternatives to fertility preser-
vation, including adoption and pregnancy through the use of donor
eggs or sperm.
Use of a donor egg will not be everyone's cup of tea, and for some it
will be morally, religiously, or emotionally out of the question. How-
ever, the use of a donor egg has much to offer those for whom the
experience of parenthood is not delimited to the transmission of
genes. It has been with us for a quarter of a century and has a track
record of success.7 In the United States, for example, 18,121 donor
oocyte cycles were performed in 2008, and 55% of recipients delivered
a live baby after a single fresh donor oocyte transfer." The success
rates are much higher-approaching 100%-if recipients undergo
multiple attempts.9
Some young women recently diagnosed with cancer will be carriers
of cancer predisposition genes. Breast ovarian cancer syndromes
(BrCal and BrCa2), retinoblastoma, and hereditary nonpolyposis
colorectal cancer are only some examples.' 0 Without any doubt, more
genes will be identified in the future. We have already seen that some
of these young people will wish to have children who are not af-
fected.11 Technology-Preimplantation Genetic Diagnosis (PGD)
7. See Maria Bustillo et al., Letter, Delivery of a Healthy Infant Following Nonsurgical Ovum
Transfer, 251 J. AM. MED. Ass'N 889 (1984); Peter Lutjen et al., The Establishment and Mainte-
nance of Pregnancy Using In Vitro Fertilization and Embryo Donation in a Patient with Primary
Ovarian Failure, 307 NATURE 174 (1984); Zev Rosenwaks et al., Pregnancy Following Transfer
of In Vitro Fertilized Donated Oocytes, 45 FERTILITY & STERILITY 417 (1986).
8. See CDC ET AL., 2008 ASSISTED REPRODUCTIVE TECHNOLOGY SUCCESS RATES: NATIONAL
SUMMARY AND FERTILITY CLINIC REPORTS 13, 24 & fig.10 (2010), available at http://www.cdc.
gov/art/ART2008/PDF/ART 2008_Full.pdf.
9. See Anna Paola Anselmo et al., Successful Pregnancies Following an Egg Donation Pro-
gram in Women with Previously Treated Hodgkin's Disease, 86 HAEMATOLOGICA 624, 626
(2001).
10. Angus J. Clarke & Clara Gaff, Challenges in the Genetic Testing of Children for Familial
Cancers, 93 ARCHIVES DISEASE CHILDHOOD 911 (2008); Kenneth Offit et al., Cancer Genetic
Testing and Assisted Reproduction, 24 J. CLINICAL ONCOLOGY 4775, 4777 tbl.1 (2006).
11. See Claire Julian-Reynier et al., Professionals Assess the Acceptability of Preimplantation
Genetic Diagnosis and Prenatal Diagnosis for Managing Inherited Predisposition to Cancer, 27 J.
CLINICAL ONCOLOGY 4475 (2009); Chantal Lammens et al., Attitude Towards Pre-Implantation
Genetic Diagnosis for Hereditary Cancer, 8 FAMILIAL CANCER 457, 461 (2009); M. Sagi et al.,
Preimplantation Genetic Diagnosis for BRCA1/2-A Novel Clinical Experience, 29 PRENATAL
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with transfer of only unaffected embryos or prenatal diagnosis with
termination of affected fetuses-offers one set of solutions. However,
these are added interventions to what is already a technology-
intensive, high-stress reproduction. Both procedures carry risks, and
when the gene is dominant, half of the embryos or fetuses so con-
ceived will be carriers. Thus, for example, everything else being
equal, a young breast cancer patient carrying a BrCa gene will find
that, if she wishes to preserve fertility through embryo freezing and
have a non-affected child, the success rate for reproductive preserva-
tion will be half that of a similar young breast cancer patient without a
genetic predisposition. Some recently diagnosed cancer patients who
carry predisposition genes will see the use of a donor egg as a simpler
solution: a proven, highly successful way to build a family and, at the
same time, eliminate a deleterious gene.
The intent here is not to minimize the cultural and emotional mean-
ing of genetic reproduction. I simply wish to emphasize that, for some
people, using a donor egg-or adoption or child-free living-is the
best possible solution to a difficult situation. Sometimes medical prac-
titioners best help patients by expanding their gaze beyond the dazzle
of what can be done to the simpler pleasures and satisfactions that
surround us all the time and that are more easily within reach.
IV. CLINICAL PRACTICE OF OOCYTE DONATION
To this end, I believe it is important that advisors discuss oocyte
donation from the beginning, and sometimes even in detail, along with
other options for fertility preservation. Some patients may want to
hear a lot about it, others may not. But it is all part of an ultimately
hopeful message that, while life may be different, it will go on.
In the very near future, the majority of oocyte donation cycles may
be done using cryopreserved and stored oocytes, similar to the current
practice of sperm banks.12 At the time of this writing, though, most
oocyte donation is done using fresh oocytes, with the cycles of donors
and recipients synchronized. The mechanics of oocyte donation thus
involve a number of steps: First, medical practitioners must recruit
suitable donors and obtain informed consent from both parties. Sec-
ond, medical practitioners stimulate the donor's ovaries to obtain mul-
tiple eggs, prepare the recipient's uterus hormonally for transfer, and
synchronize it to the donor's stimulation cycle. Finally, medical prac-
DIAGNOSis 508 (2009); Kangpu Xu et al., Preimplantation Genetic Diagnosis for Retinoblastoma:
The First Reported Liveborn, 137 AM. J. OPHTHALMOLOGY 18 (2004).
12. See Zsolt P. Nagy et al., Clinical Evaluation of the Efficiency of an Docyte Donation Pro-
gram Using Egg Cryo-Banking, 92 FERTILITY & STERILITY 520 (2009).
[Vol. 61:763768
2012] PRESERVATION OF REPRODUCTIVE POTENTIAL 769
titioners inseminate the retrieved oocytes with the appropriate sperm
and transfer the resulting embryos into the prepared recipient's
uterus.
A. Recruitment of Donors
Third-party reproduction is one of the most ethically complex as-
pects of reproductive health care. Some countries (such as Germany
and Italy) do not allow oocyte donation at all. Among societies that
do allow egg donation, even those with generally similar values may
legislate donor recruitment very differently.13 Thus, some countries
(such as Denmark, France, and Spain) have mandated anonymity
while others (Austria, Netherlands, New Zealand, Sweden, Switzer-
land, United Kingdom, and the Australian state of Victoria) have
mandated that donors be identifiable to their genetic offspring.14
Some countries (such as Canada and China) do not allow monetary
compensation or strictly regulate it, while others regulate more
loosely.15 In others (such as India and the United States), compensa-
tion is unregulated, though it may be constrained by professional
guidelines1 6 and, of course, market forces.
In the United States, it is not surprising that there is much fewer
regulation. U.S. law allows both anonymous and known donation,17
and the ASRM guidelines suggest that both are acceptable.18 Com-
pensation is not regulated. A 2007 ASRM Ethics Committee Report
set the following professional guidelines for compensation:
13. See Itziar Alkorta Idiakez, Human Tissue and Cells Regulation in Spain: Looking at Eu-
rope to Solve Inner Contradictions?, LAw & Hum. GENOME REV., July-Dec. 2008, at 25.
14. See Anonymity, 87 FERTILITY & STERILITY S1, S34-S35 tbl.9.1 (Howard W. Jones et al.
eds., Supp. 1 2007).
15. See generally Wannes Van Hoof & Guido Pennings, Extraterritorial Laws for Cross-Border
Reproductive Care: The Issue of Legal Diversity, 19 EUR. J. HEALTH L. 187 (2012). In France
donors can be compensated for documented expenses. Spain and the United Kingdom allow for
small monetary compensation and expenses.
16. Practice Comm. of the ASRM & Practice Comm. of the Soc'y for Assisted Reprod. Tech.,
2008 Guidelines for Gamete and Embryo Donation: A Practice Committee Report, 90 FERTILITY
& STERILITY S30 (Supp. III 2008) [hereinafter 2008 Guidelines]; Richard F. Storrow, Assisted
Reproduction of Treacherous Terrain: The Legal Hazards of Cross-Border Reproductive Travel,
23 REPROD. BIOMED. ONLINE 538 (2011); see also Nishat Hyder, India Debates New Surrogacy
Laws, BIONEWs (Feb. 7, 2011), http://www.bionews.org.uk/page 88796.asp2Oll.
17. In August 2011, the Washington legislature enacted a law providing a child conceived
through assisted reproduction with access to identifying information of the donor of the gametes
so long as the donor has not signed an affidavit of nondisclosure with the fertility clinic. WASH.
REV. CODE § 26.26.750 (West, Westlaw through Apr. 6, 2012). The opt-out provision still allows
both anonymous and known donation.
18. 2008 Guidelines, supra note 16.
DEPAUL LAW REVIEW
[S]ums of $5,000 or more require justification and sums above
$10,000 are not appropriate....
... To avoid putting a price on human gametes or selectively valuing
particular human traits, compensation should not vary according to
the planned use of the oocytes (e.g., research or clinical care), the
number or quality of oocytes retrieved, the outcome of prior dona-
tion cycles, or the donor's ethnic or other personal characteristics. 19
Medical professionals screen and care for American oocyte donors.
Many IVF programs recruit donors themselves. However, commer-
cial, for-profit agencies (run mostly by business people, although
sometimes by lawyers and occasionally by medical professionals) re-
cruit a large, but difficult to quantify, proportion of American donors.
There are about 150 of these independent egg donor agencies in the
United States, and only about one third assented to sign agreements
to abide by ASRM guidelines. Furthermore, a recent review of 53
websites of the assenting agencies found that, despite their signed
agreements, 24.5% advertise compensation that does not follow
ASRM guidelines. 20
For many reasons, including both the relatively recent cultural pres-
sure to delay childbearing and the comparative availability of egg do-
nors, oocyte donation is a large and growing part of American fertility
treatments. In light of this trend, it is particularly important to evalu-
ate the policies, procedures, and ethics surrounding egg donation.
B. Trans-Border Reproductive Care
Practically speaking, donor recruitment is easier when anonymity is
allowed and when donors can be compensated legally. Thus, in Eu-
rope, IVF centers performed 11,475 oocyte donation cycles in 2005,
3% of the total number of European IVF cycles done that year.21 By
contrast, in the same year, IVF centers in the United States performed
16,161 oocyte donation cycles, 12% of all 2005 U.S. IVF cycles. 2 2
It should be noted that over half of the European donor egg cycles
performed in 2005-5,875 oocyte donation cycles-were performed in
19. Ethics Comm. of the ASRM, Financial Compensation of Oocyte Donors, 88 FERTILITY &
STERILITY 305, 308 (2007) (footnote omitted).
20. Janelle Luk & John C. Petrozza, Evaluation of Compliance and Range of Fees Among
American Society for Reproductive Medicine-Listed Egg Donor and Surrogacy Agencies, 53 J.
REPROD. MED. 847, 849 (2008).
21. A. Nyboe Andersen et al., Assisted Reproductive Technology and Intrauterine Insemina-
tions in Europe, 2005: Results Generated from European Registers by ESHRE, 24 Hum. REPROD.
1267, 1269 tbl.1 (2009).
22. CDC ET AL., 2005 ASSISTED REPRODUCTIVE TECHNOLOGY SUCCESS RATES: NATIONAL
SUMMARY AND FERTILITY CLINIC REPORTS 56 (2007), available at http://www.cdc.gov/art/PDF/
508PDF/2005ART508.pdf.
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one country: Spain.23 Spain has a strong tradition of anonymous tis-
sue and organ donation and an ethical policy that allows for compen-
sation for time and expenses. A quick perusal of websites reveals that
the Spanish procedures include not only the trans-border reproductive
care of recipients, but also the trans-border recruitment of donors.24
Thus, differences in policy have fostered trans-border reproductive
care.25 Not only do recipients travel for oocyte donation services, but
centers also actively recruit donors across national borders. Not sur-
prisingly, more prosperous countries generally recruit from less pros-
perous countries. For some donors, the small stipend, travel, meals,
and hotel stay are enticing indeed, if not coercive.
In addition, the intended parents are increasingly staying in the
comfort of their own homes while gametes and embryos do the inter-
national travel. For example, an intended father's sperm may be
flown from Canada to the United States and used to create embryos
using an American egg donor, with the resulting embryos frozen and
flown back to Canada to be transferred into the Canadian recipient's
womb.
C. Anonymous Versus Known Donation
Presently, most oocyte donation worldwide is anonymous. How-
ever, family and known donation is the best choice for some recipi-
ents. This may be especially true for some cancer survivors. A sister,
cousin, or a friend may have good reason to decide to donate to a
survivor and may derive great satisfaction from the action. For the
recipient, the opportunity to have a child who is genetically related to
her family (such as a sister or cousin) or the kindness of the gift can
also make it a good choice.
However, family and known donation also carry higher risks of co-
ercion and higher risks of complicated family dynamics. This may be
particularly true when the recipient is a cancer survivor. For these
reasons, ASRM recommends psychological screening of all involved
23. Andersen et al., supra note 21, at 1269 tbl.1.
24. See Giles Tremlett, Spain Becomes the Destination of Choice for Fertility Tourists from
Britain, GUARDIAN, May 12, 2006, at 16; Claire Murphy, Rush to Spain for IVF Is Up 100pc.,
HERALD.IE (Sept. 9, 2009), http://www.herald.ie/news/rush-to-spain-for-ivf-is-up-100pc-1881428.
html.
25. Maria C. Inhorn & Pasquale Patrizio, Rethinking Reproductive "Tourism" as Reproductive
"Exile," 92 FERTILITY & STERILITY 904 (2009); G. Pennings et al., ESHRE Task Force on Ethics
and Law 15: Cross-Border Reproductive Care, 23 Hum. REPROD. 2182, 2182 (2008).
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parties-the prospective donor, recipient, and their respective part-
ners-before proceeding with a known donation. 26
Finally, "identity release" refers to donation that is anonymous at
the time of the donation, but in which donor-conceived persons, on
reaching adulthood, can request identifying information about their
donor. Generally, identity release agreements in the United States
are voluntary, and their legal status is not well defined. 27
D. Screening Procedures
1. Infectious Disease Screening of Donors
Donors in the United States must be screened for infectious-disease
risk according to detailed Food and Drug Administration (FDA)
guidelines. 28 The FDA regulations have improved some aspects of the
safety of oocyte donation. However, the regulated tests, which are
extensive and expensive, are biased toward the safety of the recipient
versus that of the donor or the donor-conceived child. For example,
there are no U.S. regulations concerning genetic testing of donors or
issues of donor safety during stimulation.
2. Genetic Screening
Genetic screening of oocyte donors is directed by guidelines rather
than laws, and the guidelines are minimal and vague, likely by inten-
tion. The only test specifically recommended for all donors is cystic
fibrosis. 29 Even so, some evidence suggests that IVF programs' com-
pliance with these minimal guidelines varies widely. In a 1999 survey,
only 22% of responding IVF programs tested oocyte donors for cystic
fibrosis. 30 Even in 2004, a survey found that only 19.5% of responding
IVF clinics met ASRM guidelines for genetic screening of oocyte do-
nors and that 25% of responding clinics did no genetic screening at
all.31
26. 2008 Guidelines, supra note 16; Ethics Comm. of the ASRM, Family Members as Gamete
Donors and Surrogates, 80 FERTILITY & STERILITY 1124 (2003).
27. But see WASH. REV. CODE § 26.26.750 (West, Westlaw through Apr. 6, 2012).
28. See 2008 Guidelines, supra note 16; U.S. DEP'T OF HEALTH & HUMAN SERVS. ET AL.,
GUIDANCE FOR INDUSTRY: ELIGIBILITY DETERMINATION FOR DONORS OF HUMAN CELLS, TIS-
SUES, AND CELLULAR AND TISSUE-BASED PRODUCTS (HCT/Ps) 3 (2007), available at http://
www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatorylnformation/Guidances/
Tissue/ucm073964.htm.
29. 2008 Guidelines, supra note 16.
30. Vivian Lewis et al., Survey of Genetic Screening for Oocyte Donors, 71 FERTILITY & STE-
RILITY 278, 279 (1999).
31. Z. Powis et al., Genetic Screening of Oocyte Donors, 82 FERTILITY & STERILITY S188, S188
(Supp. II 2004).
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It may make sense for genetic screening guidelines to be vague.
The field of genetics is progressing rapidly, and recommended screen-
ing tests change very quickly. On the other hand, the absence of strict
guidelines does not decrease practitioners' responsibility to act in the
best interests of the donor, the recipient parents, and most of all, the
potential child. The testing of oocyte donors and the dissemination of
information so acquired carry ethical, medical, and psychological im-
plications. Thus, ideally, a genetic counselor should counsel every
prospective oocyte donor before testing and should be the person who
conveys these test results when positive.32
3. Psychological Screening
Psychological evaluation of the donor, the recipient, and when ap-
plicable, their families can be extremely useful. Third-party reproduc-
tion is a complex process with potential long-term repercussions.
Participants have both the right and the responsibility to explore the
consequences and emotions that accompany these decisions. Advisors
can listen, explore feelings, support, and educate donors and recipi-
ents in a way that helps all parties to make choices that are right for
them. Psychological consultation is very helpful for all recipients of
donated oocytes and is specifically recommended for recipients con-
sidering known donation. 33 These sessions are, at least partly,
"psycho-education."
E. Matching of Donors and Recipients
Although there has been little scientific inquiry into the criteria that
make for success in families created with donated gametes, current
practice has widely included phenotypic matching. Thus, most pro-
grams worldwide include an attempt to match donors and recipients
using criteria such as coloration, height, and ethnic background. In
fact, most recipients (and donors) express interest in some degree of
phenotypic matching.
However, European donor oocyte programs are generally less con-
cerned about phenotypic matching than American ones. In addition,
several societal trends suggest that phenotypic matching may assume a
lesser role in the future. First, adoption practices have increasingly
relinquished proscriptions against interfaith and interracial adop-
32. See Judith F. Daar & Robert G. Brzyski, Genetic Screening of Sperm and Oocyte Donors:
Ethical and Policy Implications, 302 J. AM. MED. Ass'N 1702, 1703 (2009).
33. 2008 Guidelines, supra note 16; Ethics Comm. of the ASRM, supra note 26.
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tion.34 Some of these historical proscriptions have come to seem old-
fashioned or even racist. Second, there is an increased tendency for,
and increased professional advice in favor of, disclosure of means of
origin to individuals conceived through gamete. donation.35 Third,
there is a growing interest (some of it legally mandated) toward iden-
tity release donation. These trends decrease the need for secrecy that
may have been a part of phenotypic matching. Finally, families have
become more diverse and the concept of a family has been expanded.
All of these tendencies together may lessen the importance of pheno-
typic matching in the future. Nonetheles§, at the present time, most
recipients (and many donors) express interest in at least some degree
of phenotypic matching.
F. Care of the Oocyte Donor
The oocyte donor is traditionally a young healthy person who takes
on medical risks without receiving medical benefits. From an ethical
point of view, she is more like a research subject than a patient.36 The
aim of the physician caring for the oocyte donor should be to reduce
the rate of complications to as near to zero as possible.37
V. CONCLUSION
Medical practitioners in the field of oncofertility have an under-
standable desire to be optimistic and encouraging to their young can-
cer patients. However, these patients also need support as they adjust
to the very real losses that accompany a cancer diagnosis. These
losses range from the loss of both innocence and the feeling of invul-
nerability to the physical losses that accompany surgery, chemother-
apy, and radiation; to the changes in life expectations, including
potential loss of reproductive options; and, finally, to the potential loss
of life itself. A focus on technological solutions alone for quality-of-
34. See Leslie M. Singer et al., Mother-Infant Attachment in Adoptive Families, 56 CHILD DEV.
1543, 1547 (1985) (discussing the results of a study regarding interracial adoption); Sandra Scarr
& Richard A. Weinberg, The Minnesota Adoption Studies: Genetic Differences and Malleability,
54 CHILD DEV. 260 (1983) (same).
35. 2008 Guidelines, supra note 16.
36. See generally Andrea Kalfoglou, Navigating Conflict of Interest in Oocyte Donation, 1 AM.
J. BIOETHICS W-1 (2001).
37. Daniel Bodri et al., Complications Related to Ovarian Stimulation and Oocyte Retrieval in
4052 Oocyte Donor Cycles, 17 REPROD. BIOMEDICINE ONLINE 237 (2008); Kara N. Maxwell et
al., The Incidence of Both Serious and Minor Complications in Young Women Undergoing
Oocyte Donation, 90 FERTILITY & STERILITY 2165 (2008); Mark V. Sauer, Defining the Incidence
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life issues may deny the newly diagnosed cancer patient the opportu-
nity to reconsider values and to put life events in perspective.
At moments of great loss, a certain clarity may come to us. The
minutiae of daily life, once so urgent and so critical, are suddenly set
in perspective against the impermanence of all things. We know that
genetic reproduction is important to all living things, but we also know
that the genetic imprint that an individual makes is erased in a few
generations. Some of the lives that we look to for inspiration and that
have contributed so much to the world have left no genetic mark.
Those who have raised children know that they are ours only for a
brief time and that the mark of our good parenting is that they leave
us. We can impart some of this to our patients. We can also, by not
offering false promises or over-emphasizing the importance of "fix-
ing" everything, allow patients to discover some of these truths on
their own.
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